CYTK Cytokinetics, Incorporated - Common Stock
$76,68
Prix · Aoû 19, 2026
Données fondamentales au Aoû 6, 2026
Fourchette 52 semaines
$35–$88
78% of range
Note des analystes
BUY
28 analysts
Objectif de cours
$110
+43% upside
P/E (TTM)
-11.7
ROE
152.7%
Marge nette
-891.6%
À propos de Cytokinetics, Incorporated - Common Stock Présentation de l'entreprise depuis Wikipedia
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
Lire la suite
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
History
Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.
Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.
In 2004 the company completed its initial public offering (IPO).
In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.
In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.
Products
Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure. In May 2020, omecamtiv mecarbil was granted fast track designation by the FDA for the treatment of chronic HF with reduced ejection fraction. Amgen purchased an option on omecamtiv mecarbil in 2006, and the two companies extended their partnership several times. In June 2013, Cytokinetics and Amgen expanded their licensing deal for omecamtiv mecarbil to include Japan. In November 2020 Amgen elected to terminate the collaboration, effective May 20, 2021, and Cytokinetics regained worldwide rights to develop and commercialize omecamtiv mecarbil.
Reldesemtiv (previously known as CK-2127107) is a next-generation fast skeletal muscle troponin activator (FSTA) that has undergone clinical trials for ALS.
Aficamten (previously known as CK-3773274) is an oral, small-molecule myosin inhibitor, to treat hypertrophic cardiomyopathy (HCM).
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
CYTK Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$76.67
Capitalisation Boursière
$9.43B
P/E (TTM)
-11.7
BPA (TTM)
$-6.54
Revenus (TTM)
$88M
Rendement div.
—
ROE
152.7%
Dette/Capitaux propres
-0.4
Fourchette 52 semaines
$35 – $88
CYTK Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
Configure
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenus et bénéfice net
$88M
2016-12-31
→
2025-12-31
BPA
$-6.54
2016-12-31
→
2025-12-31
Flux de trésorerie libre
$-535M
2016-12-31
→
2025-12-31
Marges
-891.6%
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
Métrique
Tendance sur 5 ans
CYTK
Médiane des pairs
P/E (TTM)
-11.7
28.5
P/S (TTM)
107.1
20.1
P/B
-14.3
12.9
EV / EBITDA
-15.9
—
Price / FCF (Cours / FCF)
-17.6
—
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
Métrique
Tendance sur 5 ans
CYTK
Médiane des pairs
Operating Margin (Marge d'exploitation)
-695.4%
—
Net Profit Margin (Marge nette)
-891.6%
-48.4%
ROA
-55.5%
-28.4%
ROE
152.7%
-49.2%
Santé financière Dette, liquidité, solvabilité — solidité du bilan
Métrique
Tendance sur 5 ans
CYTK
Médiane des pairs
Debt / Equity (Dette / Capitaux propres)
-0.4
—
Current Ratio (Ratio de liquidité)
4.5
5.0
Quick Ratio (Ratio de liquidité réduite)
0.7
—
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
Métrique
Tendance sur 5 ans
CYTK
Médiane des pairs
Revenue YoY (Chiffre d'affaires YoY)
376.6%
—
Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans)
-2.4%
—
Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans)
9.5%
—
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
Métrique
Tendance sur 5 ans
CYTK
Médiane des pairs
CYTK Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
ACHAT
28 analystes
- Achat fort 6 21,4%
- Achat 19 67,9%
- Conserver 3 10,7%
- Vente 0 0,0%
- Vente forte 0 0,0%
Objectif de cours à 12 mois
20 analystes · 2026-08-18
Médiane
$107.50
← En dessous de tous les objectifs
$76.67
Bas
$85.00
Haut
$146.00
Objectif médian
$107.50
+40,2%
Objectif moyen
$109.90
+43,3%
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
-0.08%
| Période | EPS Actual | BPA est. | Surprise |
|---|---|---|---|
| 30 juin 2026 | $-1.50 | $-1.67 | 0.17% |
| 31 mars 2026 | $-1.67 | $-1.69 | 0.02% |
| 31 décembre 2025 | $-1.50 | $-1.49 | -0.01% |
| 30 septembre 2025 | $-2.55 | $-1.61 | -0.94% |
| 30 juin 2025 | $-1.12 | $-1.41 | 0.28% |
| 31 mars 2025 | $-1.39 | $-1.41 | 0.02% |
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| PRAX | $7.43B | -21.9 | 249.5% | — | -47.3% | — |
| SMMT | $13.56B | -12.1 | — | — | -235.1% | — |
| PTGX | $5.47B | -42.6 | -89.4% | -282.8% | -20.3% | — |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | — |
| APGE | $5.16B | -17.9 | — | — | — | — |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | — |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat 16
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| R&D Expense | $416M | $339M | $330M | $241M | $160M | $97M | $86M | $89M | $90M | $60M | $46M | $44M | |
| SG&A Expense | $284M | $215M | $174M | $178M | $97M | $53M | $40M | $31M | $36M | $28M | $20M | $17M | |
| Operating Expenses | $700M | $555M | $504M | $419M | $257M | $150M | $126M | $120M | $127M | $88M | $66M | $62M | |
| Operating Income | $-612M | $-536M | $-496M | $-324M | $-186M | $-94M | $-99M | $-89M | $-113M | $19M | $-37M | $-15M | |
| Interest Expense | $46M | $38M | $28M | $19M | $16M | $16M | $7M | $4M | $3M | $3M | $268.0K | $0 | |
| Interest Income | · | · | · | $11M | $1M | $5M | $4M | $4M | · | $449.0K | $156.0K | $101.0K | |
| Other Non-op | $48M | $52M | $28M | $11M | $331.0K | $5M | $5M | $4M | $3M | $464.0K | $174.0K | $108.0K | |
| Pretax Income | · | · | · | · | · | · | · | $-106M | $-128M | $16M | $-38M | $-15M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| EPS (Basic) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.41 | $-0.97 | $-0.41 | |
| EPS (Diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 | $-1.97 | · | · | $-2.59 | $0.39 | $-0.97 | $-0.41 | |
| Shares (Basic) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 39,943,000 | 38,814,000 | 35,709,000 | |
| Shares (Diluted) | 120,103 | 111,979 | 96,524 | 89,825 | 76,886 | 64,524 | · | · | 49,404,000 | 42,561,000 | 38,814,000 | 35,709,000 | |
| EBITDA | $-602M | $-527M | $-484M | $-318M | $-184M | $-92M | $-98M | $-88M | $-111M | $19M | $-37M | $-14M |
Bilan 26
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $123M | $95M | $113M | $66M | $113M | $83M | $36M | $42M | $125M | $67M | $65M | $20M | |
| Receivables | $18M | $17M | $1M | $147.0K | $52M | $4M | $5M | $2M | $1M | $24.0K | · | · | |
| Inventory | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $17M | $15M | $12M | $12M | $12M | $6M | $3M | $2M | $4M | $2M | $2M | $1M | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Assets | $917M | $1.11B | $628M | $795M | $536M | $474M | $234M | $208M | $274M | $159M | $113M | $131M | |
| PP&E (Net) | $79M | $66M | $69M | $80M | $73M | $13M | $5M | $3M | $4M | $4M | $2M | $2M | |
| PP&E (Gross) | $126M | $103M | $97M | $98M | $89M | $38M | $29M | $27M | $26M | $25M | $23M | $22M | |
| Accum. Depreciation | $47M | $37M | $28M | $17M | $16M | $25M | $24M | $24M | $23M | $21M | $21M | $20M | |
| Other Non-current Assets | $17M | $8M | $8M | $10M | $7M | $6M | · | $300.0K | $429.0K | $200.0K | $200.0K | $200.0K | |
| Total Assets | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Accounts Payable | $22M | $20M | $22M | $26M | $21M | $8M | $8M | $4M | $5M | $4M | $2M | $1M | |
| Accrued Liabilities | $83M | $55M | $43M | $44M | $34M | $19M | $12M | $16M | $17M | $18M | $8M | $5M | |
| Current Liabilities | $202M | $180M | $103M | $85M | $72M | $31M | $26M | $22M | $32M | $33M | $32M | $24M | |
| Capital Leases | $108M | $113M | $120M | $127M | $112M | $440.0K | $2M | $771.0K | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $186.0K | $1M | $4M | $0 | · | $771.0K | $1M | $142.0K | · | · | |
| Total Liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597M | $420M | $301M | $185M | $185M | $76M | $47M | $41M | |
| Long-term Debt | $288M | $620M | $639M | $650M | · | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Total Debt | $288M | $105M | $68M | $64M | $47M | $46M | $45M | $42M | $32M | $30M | $15M | · | |
| Common Stock | $123.0K | $118.0K | $102.0K | $94.0K | $84.0K | $70.0K | $59.0K | $55.0K | $54.0K | $41.0K | $40.0K | $39.0K | |
| Paid-in Capital | · | · | · | · | $1.45B | · | · | · | · | · | · | $589M | |
| Retained Earnings | $-3.49B | $-2.70B | $-2.11B | $-1.59B | $-1.21B | $-992M | $-865M | $-743M | $-646M | $-518M | $-535M | $-497M | |
| AOCI | $630.0K | $2M | $-10.0K | $-4M | $-869.0K | $149.0K | $679.0K | $500.0K | $343.0K | $137.0K | $149.0K | $-4.0K | |
| Stockholders' Equity | $-660M | $-135M | $-386M | $-108M | $244M | $113M | $-11M | $26M | $110M | $94M | $69M | $92M | |
| Liabilities + Equity | $1.42B | $1.40B | $824M | $1.01B | $841M | $534M | $290M | $211M | $295M | $170M | $115M | $133M | |
| Shares Outstanding | 122,943,172 | 118,209,139 | 101,637,922 | 94,833,975 | 84,799,542 | 71,015,183 | 59,172,124 | 54,717,906 | 53,960,832 | 40,646,595 | 39,581,692 | 38,659,738 |
Flux de trésorerie 16
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $12M | $6M | $2M | $2M | $1M | $1M | $2M | $741.0K | $589.0K | $490.0K | |
| Stock-based Comp | $112M | $98M | $72M | $48M | $27M | $18M | $11M | $10M | $9M | $7M | $5M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Other Non-cash | $153M | $86M | $28M | $36M | $44M | $117M | $19M | $-6M | $15M | $13M | $37M | $-34M | |
| Operating Cash Flow | $-510M | $-396M | $-414M | $-300M | $-143M | $9M | $-91M | $-101M | $-102M | $37M | $5M | $-45M | |
| CapEx | $25M | $4M | $1M | $11M | $49M | $11M | $3M | $889.0K | $3M | $2M | $562.0K | $1M | |
| Investing Cash Flow | $17M | $-553M | $239M | $-262M | $-148M | $-197M | $-75M | $5M | $-66M | · | · | · | |
| Net Debt Issued | $-11M | $-9M | · | $-48M | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Net Stock Activity | · | · | $164M | · | $0 | $0 | $36M | $0 | $112M | $0 | $9M | $49M | |
| Financing Cash Flow | $524M | $931M | $221M | $516M | $320M | $234M | $160M | $13M | $226M | · | · | · | |
| Net Change in Cash | $30M | $-18M | $46M | $-45M | $30M | $47M | $-6M | $-83M | $58M | $2M | $45M | $57.0K | |
| Taxes Paid | $0 | $0 | $0 | · | · | · | · | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | |
| Free Cash Flow | $-535M | $-400M | $-416M | $-311M | $-191M | $-2M | $-94M | $-102M | $-105M | $35M | $4M | $-46M | |
| Levered FCF | · | · | · | · | · | · | · | $-106M | $-108M | $33M | · | $-46M |
Rentabilité 7
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% | -168.3% | -368.0% | -282.3% | -848.3% | 17.6% | -130.5% | -31.4% | |
| Net Margin | -891.6% | -3191.1% | -6988.6% | -411.2% | -305.7% | -228.0% | -452.9% | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| Pretax Margin | · | · | · | · | · | · | · | -337.4% | -955.9% | 15.5% | -130.9% | -31.2% | |
| EBITDA Margin | -683.9% | -2851.1% | -6431.8% | -336.6% | -261.3% | -165.0% | -363.2% | -278.3% | -833.9% | 18.3% | -128.5% | -30.4% | |
| ROA | -55.5% | -53.0% | -57.2% | -41.9% | -31.3% | -30.9% | -48.6% | -42.0% | -55.0% | 11.5% | -30.2% | -13.6% | |
| ROE | 152.7% | 789.8% | 127.6% | 628.0% | -87.4% | -96.8% | 790.0% | -272.5% | -125.2% | 20.2% | -46.7% | -20.0% | |
| ROIC | · | · | · | · | · | · | · | -130.1% | -80.1% | 15.0% | -44.9% | -16.0% |
Liquidité et Solvabilité 5
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 | 15.2 | 9.0 | 9.4 | 8.5 | 4.8 | 3.6 | 5.5 | |
| Quick Ratio | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 | 2.8 | 1.6 | 2.0 | 3.9 | 2.0 | 2.1 | 0.8 | |
| Debt / Equity | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.6 | 0.3 | 0.3 | 0.2 | · | |
| LT Debt / Equity | -0.4 | -0.7 | -0.2 | -0.6 | 0.2 | 0.4 | -4.1 | 1.5 | 0.3 | 0.3 | 0.2 | · | |
| Interest Coverage | -13.4 | -14.2 | -17.5 | -16.7 | -11.3 | -5.9 | -14.9 | -23.4 | -37.6 | 6.9 | · | · |
Efficacité 2
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.7 | 0.2 | 0.4 | |
| Receivables Turnover | 5.1 | 2.1 | 10.5 | 3.6 | 2.5 | 11.7 | 7.3 | 18.8 | 23.5 | · | · | · |
Taux de croissance 3
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 376.6% | 145.3% | -92.0% | 34.3% | 26.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.4% | -36.0% | -48.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.5% | · | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM) 14
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $88M | $18M | $8M | $95M | $70M | $56M | $27M | $32M | $13M | $106M | $29M | $47M | |
| Net Income TTM | $-785M | $-590M | $-526M | $-389M | $-215M | $-127M | $-122M | $-106M | $-128M | $16M | $-38M | $-15M | |
| Market Cap | $7.81B | $5.56B | $8.49B | $4.35B | $3.87B | $1.48B | $628M | $346M | $440M | $494M | $414M | $310M | |
| Enterprise Value | $7.98B | $5.57B | $8.44B | $4.34B | $3.80B | $1.44B | $636M | $346M | $346M | $457M | $364M | · | |
| P/E | -9.7 | -8.9 | -15.3 | -10.6 | -16.3 | -10.5 | · | · | -3.1 | 31.2 | -10.8 | -19.5 | |
| P/S | 88.7 | 301.0 | 1126.9 | 45.9 | 54.9 | 26.4 | 23.4 | 11.0 | 32.9 | 4.6 | 14.4 | 6.6 | |
| P/B | -11.8 | -41.1 | -22.0 | -40.3 | 15.8 | 13.0 | -57.4 | 13.3 | 4.0 | 5.2 | 6.0 | 3.4 | |
| P / Tangible Book | · | · | · | · | 15.8 | 13.0 | · | · | · | · | · | · | |
| P / Cash Flow | -15.3 | -14.0 | -20.5 | -14.5 | -27.1 | 165.0 | -6.9 | -3.4 | -4.3 | 13.4 | 84.8 | -6.9 | |
| P / FCF | -14.6 | -13.9 | -20.4 | -14.0 | -20.2 | -699.7 | -6.7 | -3.4 | -4.2 | 14.0 | 95.8 | -6.7 | |
| EV / EBITDA | -13.2 | -10.6 | -17.4 | -13.6 | -20.6 | -15.6 | -6.5 | -3.9 | -3.1 | 23.5 | -9.9 | · | |
| EV / FCF | -14.9 | -13.9 | -20.3 | -14.0 | -19.9 | -682.3 | -6.8 | -3.4 | -3.3 | 12.9 | 84.1 | · | |
| EV / Revenue | 90.6 | 301.5 | 1121.0 | 45.9 | 54.0 | 25.8 | 23.7 | 11.0 | 25.9 | 4.3 | 12.7 | · | |
| Earnings Yield | -10.3% | -11.2% | -6.5% | -9.4% | -6.1% | -9.5% | · | · | -31.8% | 3.2% | -9.3% | -5.1% |
Compte de résultat 14
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $19M | $18M | $2M | $67M | $2M | $17M | $463.0K | $249.0K | $835.0K | $2M | $378.0K | $867.0K | $5M | $2M | $3M | |
| R&D Expense | $98M | $96M | $104M | $99M | $110M | $98M | $94M | $85M | $80M | $82M | $85M | $83M | $83M | $79M | $75M | $63M | |
| SG&A Expense | $104M | $105M | $92M | $69M | $66M | $57M | $62M | $57M | $51M | $46M | $44M | $40M | $40M | $50M | $54M | $48M | |
| Operating Expenses | $208M | $203M | $196M | $169M | $178M | $157M | $156M | $141M | $130M | $127M | $129M | $123M | $123M | $129M | $129M | $111M | |
| Operating Income | $-179M | $-184M | $-178M | $-167M | $-112M | $-156M | $-139M | $-141M | $-130M | $-126M | $-127M | $-122M | $-122M | $-124M | $-127M | $-108M | |
| Interest Expense | · | · | $14M | $11M | $11M | · | $9M | $9M | $13M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| Other Non-op | $14M | $11M | $11M | $10M | $13M | $14M | $15M | $17M | $12M | $8M | $8M | $7M | $7M | $6M | $6M | $4M | |
| Net Income | $-199M | $-206M | $-183M | $-306M | $-134M | $-161M | $-150M | $-161M | $-143M | $-136M | $-137M | $-129M | $-129M | $-131M | $-137M | $-142M | |
| EPS (Basic) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| EPS (Diluted) | $-1.50 | $-1.67 | $-1.51 | $-2.55 | $-1.12 | $-1.36 | $-1.26 | $-1.36 | $-1.31 | $-1.33 | $-1.38 | $-1.35 | $-1.34 | $-1.38 | $-1.53 | $-1.52 | |
| Shares (Basic) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| Shares (Diluted) | 132,086 | 123,273 | -237,832 | 119,982 | 119,457 | 118,496 | -216,870 | 117,685 | 109,240 | 101,924 | -190,466 | 96,071 | 95,755 | 95,164 | -174,660 | 93,758 | |
| EBITDA | $-179M | $-180M | · | $-167M | $-112M | $-153M | · | $-141M | $-130M | $-124M | · | $-122M | $-122M | $-123M | · | $-108M |
Bilan 24
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $255M | $130M | $123M | $225M | $75M | $74M | $95M | $47M | $190M | $120M | · | $100M | $69M | $102M | · | $106M | |
| Receivables | $24M | $7M | $18M | $2M | $8M | $2M | $17M | $244.0K | $0 | $834.0K | · | $2M | $985.0K | $1M | · | $2M | |
| Inventory | $380.0K | $154.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $14M | $17M | $13M | $20M | $16M | $15M | $7M | $11M | $19M | · | $20M | $20M | $16M | · | $14M | |
| Current Assets | $1.21B | $839M | $917M | $977M | $887M | $956M | $1.11B | $1.02B | $1.07B | $639M | · | $561M | $587M | $681M | · | $884M | |
| PP&E (Net) | $79M | $82M | $79M | $76M | $70M | $67M | $66M | $64M | $66M | $68M | · | $76M | $77M | $79M | · | $80M | |
| PP&E (Gross) | · | · | $126M | · | · | · | $103M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $37M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $19M | $18M | $17M | $17M | $15M | $13M | $8M | $8M | $8M | $8M | · | $8M | $8M | $8M | · | · | |
| Total Assets | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Accounts Payable | $21M | $25M | $22M | $22M | $16M | $14M | $20M | $12M | $9M | $13M | · | $14M | $13M | $17M | · | $14M | |
| Accrued Liabilities | $77M | $69M | $83M | $62M | $52M | $43M | $55M | $50M | $40M | $40M | · | $33M | $31M | $36M | · | $40M | |
| Current Liabilities | $181M | $199M | $202M | $142M | $131M | $160M | $180M | $110M | $103M | $89M | · | $78M | $66M | $75M | · | $76M | |
| Capital Leases | $102M | $105M | $108M | $111M | $111M | $113M | $113M | $115M | $117M | $119M | · | $122M | $124M | $125M | · | $114M | |
| Other Non-current Liabilities | · | · | · | $2M | $2M | $3M | · | $0 | $0 | $2.0K | · | $408.0K | $625.0K | $837.0K | · | $1M | |
| Total Liabilities | $2.10B | $2.10B | $2.08B | $1.96B | $1.59B | $1.53B | $1.54B | $1.45B | $1.42B | $1.20B | · | $1.18B | $1.11B | $1.12B | · | $1.09B | |
| Long-term Debt | $276M | $292M | $288M | $1.00B | $610M | $610M | $105M | $620M | $629M | $630M | · | · | · | · | · | · | |
| Total Debt | $276M | $292M | · | $176M | $173M | $105M | · | $105M | $104M | $68M | · | $61M | $62M | $64M | · | $64M | |
| Common Stock | $138.0K | $124.0K | $123.0K | $122.0K | $119.0K | $119.0K | $118.0K | $118.0K | $117.0K | $105.0K | · | $94.0K | $94.0K | $94.0K | · | $93.0K | |
| Retained Earnings | $-3.89B | $-3.69B | $-3.49B | $-3.30B | $-3.00B | $-2.86B | $-2.70B | $-2.55B | $-2.39B | $-2.25B | · | $-1.98B | $-1.85B | $-1.72B | · | $-1.45B | |
| AOCI | $-4M | $-2M | $630.0K | $34.0K | $-158.0K | $2M | $2M | $5M | $-1M | $-539.0K | · | $-874.0K | $-1M | $-2M | · | $-6M | |
| Stockholders' Equity | $-173M | $-827M | $-660M | $-521M | $-369M | $-266M | $-135M | $-14M | $109M | $-396M | $-386M | $-439M | $-333M | $-229M | $-108M | $-16M | |
| Liabilities + Equity | $1.92B | $1.27B | $1.42B | $1.44B | $1.23B | $1.26B | $1.40B | $1.44B | $1.52B | $808M | · | $741M | $780M | $890M | · | $1.08B | |
| Shares Outstanding | · | · | 122,943,172 | · | · | · | 118,209,139 | · | · | · | · | · | · | · | · | · |
Flux de trésorerie 12
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $2M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $36M | $30M | $31M | $31M | $28M | $24M | $26M | $25M | $25M | $22M | $19M | $19M | $19M | $15M | $13M | $13M | |
| Other Non-cash | · | $27M | · | · | · | $4M | · | · | · | $-18M | · | · | · | $-8M | · | · | |
| Operating Cash Flow | $-160M | $-145M | $-143M | $-108M | $-128M | $-132M | $-66M | $-102M | $-99M | $-130M | $-74M | $-96M | $-122M | $-122M | $-98M | $-84M | |
| CapEx | $4M | $6M | $6M | $9M | $4M | $6M | $1M | $701.0K | $2M | $0 | $77.0K | $220.0K | $717.0K | $402.0K | $3M | $6M | |
| Investing Cash Flow | $-507M | $145M | $-71M | $-71M | $53M | $106M | $111M | $-45M | $-652M | $33M | $-81M | $73M | $82M | $165M | $29M | $-292M | |
| Net Debt Issued | · | $-3M | · | · | · | $-3M | · | · | · | $-705.0K | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | · | · | · | $94M | · | · | · | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $94M | · | · | · | · | · | · | |
| Financing Cash Flow | $793M | $8M | $111M | $330M | $79M | $5M | $2M | $3M | $821M | $104M | $169M | $54M | $5M | $-7M | $30M | $389M | |
| Net Change in Cash | $125M | $7M | $-103M | $152M | $2M | $-21M | $48M | $-143M | $70M | $7M | $13M | $31M | $-34M | $36M | $-39M | $13M | |
| Free Cash Flow | · | $-151M | · | · | · | $-137M | · | · | · | $-130M | · | · | · | $-123M | · | · |
Rentabilité 5
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -626.0% | -948.7% | · | -8613.4% | -167.0% | -9856.3% | · | -30410.6% | -52277.9% | -15118.0% | · | -32345.2% | -14077.2% | -2698.3% | · | -4311.8% | |
| Net Margin | -694.4% | -1064.5% | · | -15815.0% | -201.3% | -10220.1% | · | -34675.0% | -57557.4% | -16244.7% | · | -34238.6% | -14837.0% | -2846.1% | · | -5658.4% | |
| EBITDA Margin | -626.0% | -931.2% | · | -8613.4% | -167.0% | -9710.6% | · | -30410.6% | -52277.9% | -14838.8% | · | -32345.2% | -14077.2% | -2658.2% | · | -4311.8% | |
| ROA | -12.6% | -16.2% | · | -21.3% | -9.8% | -15.6% | · | -14.8% | -12.4% | -16.0% | · | -14.2% | -16.6% | -15.0% | · | -14.9% | |
| ROE | 73.3% | 37.7% | · | 114.5% | 103.3% | 48.7% | · | 70.9% | 127.6% | 43.4% | · | 56.9% | 116.1% | 232.9% | · | -122.1% |
Liquidité et Solvabilité 5
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 4.2 | · | 6.9 | 6.8 | 6.0 | · | 9.3 | 10.4 | 7.2 | · | 7.2 | 8.9 | 9.0 | · | 11.6 | |
| Quick Ratio | 1.5 | 0.7 | · | 1.6 | 0.6 | 0.5 | · | 0.4 | 1.9 | 1.4 | · | 1.3 | 1.1 | 1.4 | · | 1.4 | |
| Debt / Equity | -1.6 | -0.4 | · | -0.3 | -0.5 | -0.4 | · | -7.5 | 1.0 | -0.2 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| LT Debt / Equity | -1.4 | -0.3 | · | -0.3 | -0.4 | -0.3 | · | -6.7 | 0.9 | -0.1 | · | -0.1 | -0.2 | -0.3 | · | -4.0 | |
| Interest Coverage | · | · | · | -14.7 | -10.1 | · | · | -15.8 | -10.2 | -17.8 | · | -17.1 | -17.3 | -17.9 | · | -15.9 |
Efficacité 2
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.7 | 4.4 | · | 1.9 | 15.9 | 1.1 | · | 0.3 | 0.5 | 0.9 | · | 0.2 | 0.6 | 1.3 | · | 1.7 |
Valorisation (TTM) 4
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $117M | $90M | · | $71M | $69M | $3M | · | $2M | $2M | $7M | · | $8M | $97M | $97M | · | $98M | |
| Net Income TTM | $-845M | $-808M | · | $-762M | $-600M | $-601M | · | $-569M | $-537M | $-525M | · | $-532M | $-422M | $-383M | · | $-328M | |
| P/E | -12.5 | -9.8 | · | -8.6 | -6.4 | -7.5 | · | -9.9 | -10.2 | -13.0 | · | -5.3 | -7.3 | -8.4 | · | -12.9 | |
| Earnings Yield | -8.0% | -10.2% | · | -11.6% | -15.6% | -13.3% | · | -10.1% | -9.8% | -7.7% | · | -19.0% | -13.7% | -11.9% | · | -7.7% |
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
Compte de résultat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenu | $88M | $18M | $8M | $95M | $70M |
| Marge d'exploitation % | -695.4% | -2902.7% | -6589.7% | -342.8% | -264.5% |
| Résultat net | $-785M | $-590M | $-526M | $-389M | $-215M |
| BPA dilué | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
Bilan
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dette / Capitaux propres | -0.4 | -0.8 | -0.2 | -0.6 | 0.2 |
| Ratio de liquidité | 4.5 | 6.2 | 6.1 | 9.4 | 7.5 |
| Ratio de liquidité réduite | 0.7 | 0.6 | 1.1 | 0.8 | 2.3 |
Flux de trésorerie
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $-535M | $-400M | $-416M | $-311M | $-191M |
Dernières actualités Actualités récentes mentionnant cette entreprise
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
📊
Choisissez les indicateurs qui vous importent — cliquez sur le ➕ à côté de n'importe quelle ligne dans Fondamentaux Complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.
Détenteurs institutionnels (13F) 539 déclarants · $9.0B total · Au 30 juin 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
Activité institutionnelle — Q2 2026 vs trimestre précédent
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 104 (+7 vs T. préc.) | 49 (-8 vs T. préc.) | 222 (+45 vs T. préc.) | 112 (-32 vs T. préc.) | +17.8M |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | $571 778 157 | 6 711 799 | 6,37% | Actions |
| STATE STREET CORP | $553 243 709 | 6 494 233 | 6,16% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $521 151 103 | 6 117 515 | 5,80% | Actions |
| WELLINGTON MANAGEMENT GROUP LLP | $509 521 049 | 5 980 996 | 5,68% | Actions |
| Avoro Capital Advisors LLC | $425 949 915 | 4 999 999 | 4,74% | Actions |
| FMR LLC | $375 035 430 | 4 402 341 | 4,18% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $259 207 450 | 3 042 018 | 2,89% | Actions |
| BANK OF AMERICA CORP /DE/ | $251 706 463 | 2 954 648 | 2,80% | Actions |
| RTW INVESTMENTS, LP | $243 814 036 | 2 862 003 | 2,72% | Actions |
| Polar Capital Holdings Plc | $191 988 358 | 2 253 649 | 2,14% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $161 060 214 | 1 890 600 | 1,79% | Option d'achat |
| Capital Research Global Investors | $143 683 584 | 1 686 625 | 1,60% | Actions |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $136 597 224 | 1 603 442 | 1,52% | Actions |
| Integral Health Asset Management, LLC | $136 304 000 | 1 600 000 | 1,52% | Actions |
| Point72 Asset Management, L.P. | $135 257 185 | 1 587 712 | 1,51% | Actions |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $133 386 924 | 1 565 758 | 1,49% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $131 998 327 | 1 549 458 | 1,47% | Actions |
| PRINCIPAL FINANCIAL GROUP INC | $111 435 932 | 1 308 087 | 1,24% | Actions |
| Capital International Investors | $111 245 191 | 1 305 848 | 1,24% | Actions |
| ARMISTICE CAPITAL, LLC | $106 487 500 | 1 250 000 | 1,19% | Option d'achat |
| ARMISTICE CAPITAL, LLC | $102 342 325 | 1 201 342 | 1,14% | Actions |
| Pictet Asset Management Holding SA | $99 038 455 | 1 160 463 | 1,10% | Actions |
| Frazier Life Sciences Management, L.P. | $98 810 092 | 1 159 879 | 1,10% | Actions |
| Holocene Advisors, LP | $97 506 685 | 1 144 579 | 1,09% | Actions |
| Woodline Partners LP | $93 769 315 | 1 100 708 | 1,04% | Actions |
| NORGES BANK | $86 512 319 | 1 015 522 | 0,96% | Actions |
| Royalty Pharma Sub-Manager, LLC | $83 519 594 | 980 392 | 0,93% | Actions |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $81 937 000 | 961 815 | 0,91% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $77 218 175 | 906 423 | 0,86% | Actions |
| CITADEL ADVISORS LLC | $77 062 874 | 904 600 | 0,86% | Option d'achat |
| Melqart Asset Management (UK) Ltd | $65 385 455 | 767 525 | 0,73% | Actions |
| Siren, L.L.C. | $64 655 121 | 758 952 | 0,72% | Actions |
| Fisher Asset Management, LLC | $63 355 547 | 743 697 | 0,71% | Actions |
| Foresite Capital Management IV, LLC | $60 884 867 | 714 695 | 0,68% | Actions |
| Balyasny Asset Management L.P. | $60 599 821 | 711 349 | 0,67% | Actions |
| Deep Track Capital, LP | $59 633 000 | 700 000 | 0,66% | Actions |
| JANE STREET GROUP, LLC | $59 633 000 | 700 000 | 0,66% | Option d'achat |
| BNP PARIBAS FINANCIAL MARKETS | $58 702 470 | 689 077 | 0,65% | Actions |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | $56 251 809 | 660 310 | 0,63% | Actions |
| CITADEL ADVISORS LLC | $54 601 338 | 640 936 | 0,61% | Actions |
| GOLDMAN SACHS GROUP INC | $54 053 311 | 634 503 | 0,60% | Actions |
| Qube Research & Technologies Ltd | $48 774 257 | 572 535 | 0,54% | Actions |
| EVENTIDE ASSET MANAGEMENT, LLC | $48 081 832 | 564 398 | 0,54% | Actions |
| Affinity Asset Advisors, LLC | $46 854 500 | 550 000 | 0,52% | Actions |
| First Turn Management, LLC | $44 930 228 | 527 412 | 0,50% | Actions |
| AMERICAN CENTURY COMPANIES INC | $44 162 525 | 518 398 | 0,49% | Actions |
| Caption Management, LLC | $43 651 356 | 512 400 | 0,49% | Option d'achat |
| D. E. Shaw & Co., Inc. | $40 874 247 | 479 801 | 0,46% | Actions |
| Checkpoint Capital L.P. | $40 465 250 | 475 000 | 0,45% | Actions |
| Hood River Capital Management LLC | $39 977 367 | 469 273 | 0,45% | Actions |
| RP Management, LLC | $39 401 954 | 980 392 | 0,44% | Actions |
| EMERALD ADVISERS, LLC | $39 013 272 | 457 956 | 0,43% | Actions |
| ADAR1 Capital Management, LLC | $39 009 097 | 457 907 | 0,43% | Actions |
| AMERIPRISE FINANCIAL INC | $38 010 006 | 446 179 | 0,42% | Actions |
| Candriam S.C.A. | $37 708 477 | 443 066 | 0,42% | Actions |
| MARSHALL WACE, LLP | $36 259 335 | 425 629 | 0,40% | Actions |
| RHUMBLINE ADVISERS | $35 933 015 | 421 799 | 0,40% | Actions |
| CITADEL ADVISORS LLC | $35 882 028 | 421 200 | 0,40% | Option de vente |
| ALLIANCEBERNSTEIN L.P. | $35 327 299 | 535 993 | 0,39% | Actions |
| GILDER GAGNON HOWE & CO LLC | $34 096 829 | 400 245 | 0,38% | Actions |
| TD Asset Management Inc | $32 809 225 | 385 130 | 0,37% | Actions |
| BlackRock, Inc. | $29 124 928 | 341 882 | 0,32% | Actions |
| GSK plc | $29 001 573 | 340 434 | 0,32% | Actions |
| TWO SIGMA INVESTMENTS, LP | $27 040 243 | 317 411 | 0,30% | Actions |
| CITIGROUP INC | $26 852 314 | 315 205 | 0,30% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $24 671 024 | 289 600 | 0,27% | Option de vente |
| Trails Edge Capital Partners, LP | $24 542 302 | 288 089 | 0,27% | Actions |
| EMERALD MUTUAL FUND ADVISERS TRUST | $23 833 521 | 279 769 | 0,27% | Actions |
| Polaris Capital Management, LLC | $22 737 211 | 266 900 | 0,25% | Actions |
| SEGALL BRYANT & HAMILL, LLC | $21 899 197 | 257 063 | 0,24% | Actions |
| Alyeska Investment Group, L.P. | $21 297 500 | 250 000 | 0,24% | Actions |
| ExodusPoint Capital Management, LP | $21 234 374 | 249 259 | 0,24% | Actions |
| Capital World Investors | $21 196 550 | 248 815 | 0,24% | Actions |
| Walleye Capital LLC | $20 422 428 | 239 728 | 0,23% | Actions |
| E. Ohman J:or Asset Management AB | $19 823 223 | 300 762 | 0,22% | Actions |
| Sarissa Capital Management LP | $19 476 393 | 228 623 | 0,22% | Actions |
| Swiss National Bank | $18 946 256 | 222 400 | 0,21% | Actions |
| SPHERA FUNDS MANAGEMENT LTD. | $18 740 693 | 219 987 | 0,21% | Actions |
| BAKER BROS. ADVISORS LP | $17 997 836 | 211 267 | 0,20% | Actions |
| California Public Employees Retirement System | $17 979 520 | 211 052 | 0,20% | Actions |
| Nicholas Investment Partners, LP | $17 810 758 | 209 071 | 0,20% | Actions |
| PINNACLE ASSOCIATES LTD | $17 245 864 | 202 440 | 0,19% | Actions |
| Mirador Capital Partners LP | $17 239 900 | 202 370 | 0,19% | Actions |
| Tri Locum Partners LP | $16 526 860 | 194 000 | 0,18% | Actions |
| PFM Health Sciences, LP | $16 329 730 | 191 686 | 0,18% | Actions |
| Rock Springs Capital Management LP | $16 014 016 | 187 980 | 0,18% | Actions |
| PRUDENTIAL FINANCIAL INC | $15 933 512 | 187 035 | 0,18% | Actions |
| DAFNA Capital Management LLC | $14 652 510 | 171 998 | 0,16% | Actions |
| Ghisallo Capital Management LLC | $14 482 300 | 170 000 | 0,16% | Actions |
| Impax Asset Management Group plc | $14 056 350 | 165 000 | 0,16% | Actions |
| Lombard Odier Asset Management (Europe) Ltd | $13 494 096 | 158 400 | 0,15% | Option d'achat |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | $13 383 349 | 157 100 | 0,15% | Actions |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $13 330 276 | 156 477 | 0,15% | Actions |
| JANE STREET GROUP, LLC | $12 735 905 | 149 500 | 0,14% | Option de vente |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $12 145 719 | 139 190 | 0,14% | Actions |
| Retirement Systems of Alabama | $11 962 891 | 140 426 | 0,13% | Actions |
| MetLife Investment Management, LLC | $11 930 519 | 140 046 | 0,13% | Actions |
| Polymer Capital Management (HK) LTD | $11 777 943 | 138 255 | 0,13% | Actions |
| Cinctive Capital Management LP | $11 742 419 | 137 838 | 0,13% | Actions |
| TUDOR INVESTMENT CORP ET AL | $11 279 156 | 132 400 | 0,13% | Option d'achat |
Initiés de la société 52 initiés · 18 dirigeants · 22 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Sung Lee | EVP, Chief Financial Officer | 1 juillet 2026 M | 63 221 | 0 | 5 | $-5 695 855 |
| Ching Jaw | SVP Finance & CFO | 6 mars 2023 A | 87 346 | 0 | 0 | $0 |
| Sharon Surrey Barbari | EVP, Finance & CFO | 28 février 2017 F | 40 323 | 0 | 0 | $0 |
| Fady Ibraham Malik | EVP Research & Development | 18 août 2026 M | 153 902 | 0 | 22 | $-4 429 370 |
| Andrew Callos | EVP, Chief Commercial Officer | 30 juillet 2026 M | 58 555 | 0 | 24 | $-15 318 893 |
| Jeffrey Hessekiel | Chief Legal & Admin Officer | 15 mars 2026 A | 107 943 | 0 | 0 | $0 |
| Robert Wong | VP, Chief Accounting Officer | 3 décembre 2024 A | 18 655 | 0 | 0 | $0 |
| Brett A Pletcher | EVP, Chief Legal Officer | 30 août 2024 A | 33 140 | 0 | 0 | $0 |
| Mark A Schlossberg | SVP - Legal & General Counsel | 15 mars 2022 M | 103 408 | 0 | 0 | $0 |
| David Cragg | Chief HR & Admin Officer | 7 mars 2022 F | 153 233 | 0 | 0 | $0 |
| Caryn Gordon Mcdowell | GC & Chief Compliance Officer | 27 février 2018 A | 32 548 | 0 | 0 | $0 |
| Peter S Roddy | SVP Finance & CAO | 27 février 2018 A | 21 520 | 0 | 0 | $0 |
| Bradley Paul Morgan | SVP Drug Discovery & Early Dev | 31 août 2017 M | 46 441 | 0 | 0 | $0 |
| Bonnie Charpentier | SVP Regulatory & Compliance | 28 février 2017 A | 29 004 | 0 | 0 | $0 |
| Andrew A Wolff | SVP & CMO | 28 février 2017 A | 47 255 | 0 | 0 | $0 |
| David J Morgans JR | EVP-Preclinical R&D | 28 février 2011 A | 42 000 | 0 | 0 | $0 |
| Michael Rabson | SVP Business Dev/Legal & GC | 18 décembre 2009 M | 20 043 | 0 | 0 | $0 |
| Jay K Trautman | VP, Discovery Research | 29 février 2008 A | 47 896 | 0 | 0 | $0 |
| Robert Arthur Harrington | Administrateur | 15 juillet 2026 A | 21 932 | 0 | 2 | $-248 260 |
| James M Daly | Administrateur | 15 juillet 2026 A | 3 390 | 0 | 0 | $0 |
| Edward M. Kaye MD | Administrateur | 15 juillet 2026 A | 10 434 | 0 | 6 | $-3 544 372 |
| Nancy Wysenski | Administrateur | 15 juillet 2026 A | 33 992 | 0 | 0 | $0 |
| Wendell Wierenga | Administrateur | 15 juillet 2026 A | 35 563 | 0 | 3 | $-1 881 925 |
| John T Henderson | Administrateur | 15 juillet 2026 A | 78 360 | 0 | 2 | $-2 078 525 |
| Lynne B Parshall | Administrateur | 1 juin 2026 S | 15 784 | 0 | 3 | $-1 000 100 |
| Muna Bhanji | Administrateur | 27 mai 2026 A | 26 361 | 0 | 0 | $0 |
| Robert E Landry | Administrateur | 27 mai 2026 A | 10 184 | 0 | 0 | $0 |
| Wendall Wierenga | Administrateur | 15 juillet 2025 A | 32 345 | 0 | 0 | $0 |
| COSTA SANTO J | Administrateur | 15 mai 2024 A | 20 600 | 0 | 0 | $0 |
| Sandford D Smith | Administrateur | 2 janvier 2024 A | 18 801 | 0 | 0 | $0 |
| Robert Califf | Administrateur | 3 janvier 2022 A | 6 003 | 0 | 0 | $0 |
| GAGE L PATRICK | Administrateur | 8 novembre 2021 M | 28 932 | 0 | 0 | $0 |
| Denise Gilbert | Administrateur | 20 mai 2015 J | — | 0 | 0 | $0 |
| Stephen M Dow | Administrateur | 2 janvier 2013 A | 1 421 052 | 0 | 0 | $0 |
| James A Spudich | Administrateur | 18 mai 2011 A | 180 600 | 0 | 0 | $0 |
| Grant A Heidrich III | Administrateur | 3 janvier 2011 A | 93 755 | 0 | 0 | $0 |
| Michael Schmertzler | Administrateur | 3 juin 2010 S | 4 340 923 | 0 | 0 | $0 |
| Mark Mcdade | Administrateur | 21 mai 2009 A | — | 0 | 0 | $0 |
| Charles J Homcy | Administrateur | 22 mai 2008 A | — | 0 | 0 | $0 |
| William J Rutter | Administrateur | 29 avril 2004 C | 172 413 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VI LP | Détenteur de 10% | 29 avril 2004 C | 1 615 716 | 0 | 0 | $0 |
| SRB ASSOCIATES VIII LP | Détenteur de 10% | 29 avril 2004 C | 771 052 | 0 | 0 | $0 |
| SRB ASSOCIATES VII LP | Détenteur de 10% | 29 avril 2004 C | 650 000 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VIII LP | Détenteur de 10% | 29 avril 2004 C | 755 631 | 0 | 0 | $0 |
| Robert I Blum | — | 10 août 2026 M | 377 820 | 0 | 19 | $-9 702 097 |
| Elisabeth Schnieders | — | 28 février 2017 A | 43 919 | 0 | 0 | $0 |
| James H Sabry | — | 3 juin 2010 M | 0 | 0 | 0 | $0 |
| SEVIN ROSEN VII AFFILIATES FUND LP | — | 29 avril 2004 C | 24 050 | 0 | 0 | $0 |
| SEVIN ROSEN FUND VII LP | — | 29 avril 2004 C | 625 950 | 0 | 0 | $0 |
| SRB ASSOCIATES VI LP | — | 29 avril 2004 C | 1 742 951 | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Détention d'ETF Détenu par 84 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| LFSC · RBB Fund, Inc. | 3,16% | 43 268 NS | 31 mai 2026 | N-PORT |
| HRTS · Tema ETF Trust | 2,52% | 17 069 NS | 31 mai 2026 | N-PORT |
| PTH · Invesco Exchange-Traded Fund Trust | 1,81% | 58 136 SH | 8 août 2026 | Quotidien |
| FMED · Fidelity Covington Trust | 1,55% | 8 262 NS | 31 mai 2026 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 1,40% | 3 663 NS | 31 mai 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1,24% | 189 801 NS | 30 avril 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,98% | 48 338 NS | 30 avril 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,94% | 76 297 NS | 30 avril 2026 | N-PORT |
| IBB · iShares Trust | 0,75% | 874 995 SH | 8 août 2026 | Quotidien |
| BBC · ETFis Series Trust I | 0,75% | 4 355 NS | 30 avril 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,71% | 7 377 SH | 8 août 2026 | Quotidien |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,64% | 102 933 SH | 8 août 2026 | Quotidien |
| IWN · iShares Trust | 0,62% | 1 099 434 SH | 8 août 2026 | Quotidien |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,51% | 41 612 NS | 30 avril 2026 | N-PORT |
| BIB · ProShares Trust | 0,47% | 4 553 NS | 31 mai 2026 | N-PORT |
| NUSC · Nushares ETF Trust | 0,47% | 94 565 NS | 30 avril 2026 | N-PORT |
| MIDE · DBX ETF Trust | 0,41% | 178 NS | 29 mai 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,37% | 21 543 SH | 8 août 2026 | Quotidien |
| XJH · iShares Trust | 0,35% | 18 349 SH | 8 août 2026 | Quotidien |
| IQSM · New York Life Investments ETF Trust | 0,34% | 16 959 NS | 30 avril 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,34% | 761 130 SH | 8 août 2026 | Quotidien |
| IWM · iShares Trust | 0,34% | 3 349 200 SH | 8 août 2026 | Quotidien |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 72 343 SH | 8 août 2026 | Quotidien |
| VBK · VANGUARD INDEX FUNDS | 0,32% | 1 797 986 SH | 8 août 2026 | Quotidien |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,32% | 219 413 SH | 8 août 2026 | Quotidien |
| IJK · iShares Trust | 0,32% | 429 311 SH | 8 août 2026 | Quotidien |
| ISCG · iShares Trust | 0,32% | 38 968 SH | 8 août 2026 | Quotidien |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,31% | 53 623 SH | 8 août 2026 | Quotidien |
| IJH · iShares Trust | 0,30% | 4 684 495 SH | 8 août 2026 | Quotidien |
| IJJ · iShares Trust | 0,29% | 317 724 SH | 8 août 2026 | Quotidien |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,26% | 55 086 NS | 30 avril 2026 | N-PORT |
| ITWO · ProShares Trust | 0,25% | 6 062 NS | 31 mai 2026 | N-PORT |
| RSSL · Global X Funds | 0,23% | 51 834 NS | 30 avril 2026 | N-PORT |
| PTMC · Pacer Funds Trust | 0,23% | 14 028 NS | 30 avril 2026 | N-PORT |
| MVV · ProShares Trust | 0,22% | 4 565 NS | 31 mai 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,21% | 635 330 NS | 31 mai 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,20% | 19 862 NS | 30 avril 2026 | N-PORT |
| ESML · iShares Trust | 0,20% | 72 711 SH | 8 août 2026 | Quotidien |
| SCHM · SCHWAB STRATEGIC TRUST | 0,19% | 356 940 NS | 31 mai 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0,19% | 37 821 NS | 30 avril 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,17% | 40 586 SH | 8 août 2026 | Quotidien |
| ISCB · iShares Trust | 0,16% | 5 525 SH | 8 août 2026 | Quotidien |
| MIDU · Direxion Shares ETF Trust | 0,15% | 2 025 NS | 30 avril 2026 | N-PORT |
| UMDD · ProShares Trust | 0,15% | 638 NS | 31 mai 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,15% | 11 444 NS | 30 avril 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,15% | 47 609 NS | 30 avril 2026 | N-PORT |
| UWM · ProShares Trust | 0,15% | 4 765 NS | 31 mai 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,15% | 2 868 NS | 30 avril 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,14% | 3 113 794 SH | 8 août 2026 | Quotidien |
| VHT · VANGUARD WORLD FUND | 0,14% | 333 056 SH | 8 août 2026 | Quotidien |